PANTHERx Rare to exclusively distribute Kygevvi for TK2d

PANTHERx Rare is the largest independent rare pharmacy in the United States and places a strong emphasis on the patient journey.

In a recent press release, pharmaceutical company UCB shared that they have chosen PANTHERx Rare as as the exclusive specialty pharmacy to distribute doxecitine and doxribtimine, marketed as Kygevvi, for the treatment of thymidine kinase 2 deficiency (TK2d).

PANTHERx is a United States-based pharmacy that specializes in drugs for individuals with rare diseases. Licensed in all 50 states, it is currently the largest independent rare pharmacy in the country.

“We are proud to partner with UCB to support access to KYGEVVI and deliver the hyper-personalized care for eligible people who are prescribed KYGEVVI,” said Bansi Nagji, chief executive officer of PANTHERx. “By providing dedicated, patient-centered support through our experienced RxARECARE teams, we aim to reduce the burden on patients and their families and help improve their treatment experiences.”

PANTHERx strongly emphasizes the patient journey, helping individuals to navigate the complexities of health care systems by creating personalized care plans. In doing so, they aim to make the process of accessing treatment less overwhelming for patients.

Read more about TK2d therapies

What separates a rare pharmacy from a local one is the level of expertise. Staff members are specially trained in rare disease and are equipped to manage challenges related to dosing and side effects.

PANTHERx also offers numerous resources to help individuals feel supported at all times. These include an introductory call to describe their services and provide medication counseling, followed by monthly calls to monitor progress. Doctors are available 24/7 to answer any questions as well.

In addition to patient support, PANTHERx ships medication for free to all homes in the United States and its territories. Patient assistance staff can help identify resources to reduce financial burden upon request, too.

Doxecitine and doxribtimine is an oral treatment for TK2d that works by providing the body with the DNA building blocks deoxycytidine and deoxythymidine. This helps the cells to maintain and replicate mitochondrial DNA.

Sign up here to get the latest news, perspectives, and information about TK2d sent directly to your inbox. Registration is free and only takes a minute.